Lyvgen Biopharma Holdings Limited
6 clinical trials · Sponsor
◉ Watch Lyvgen Biopharma Holdings Limited
| Record | Firm | Date |
|---|---|---|
| A Study of LVGN6051 Combination Therapy in Patient With Head and Neck Squamous Cell Carcinoma (HNSCC) (NCT06378177) | Lyvgen Biopharma Holdings Limited | 2024-06-21 |
| A Study of LVGN6051 Combined With Anlotinib in Patient With Soft Tissue Sarcoma (NCT05301764) | Lyvgen Biopharma Holdings Limited | 2022-05-25 |
| Study of LVGN7409 (CD40 Agonist Antibody) in Locally Advanced, Metastatic or Recurrent/Refractory Malignancy (NCT05152212) | Lyvgen Biopharma Holdings Limited | 2021-09-29 |
| Study of LVGN6051 (CD137 Agonist Antibody) in Advanced or Metastatic Malignancy (NCT04694781) | Lyvgen Biopharma Holdings Limited | 2021-05-14 |
| Phase 1 Trial of LVGN7409 (CD40 Agonist Antibody) as Single Agent and Combination Therapies in Advanced or Metastatic Malignancy (NCT04635995) | Lyvgen Biopharma Holdings Limited | 2020-12-11 |
| Phase 1 Trial of LVGN6051 as Single Agent and in Combination With Keytruda (Pembrolizumab) in Advanced or Metastatic Malignancy (NCT04130542) | Lyvgen Biopharma Holdings Limited | 2019-10-31 |
Track Lyvgen Biopharma Holdings Limited automatically
Every clearance here is in the API, with alerts when new ones post.